Overview

• Biotech firm's Q4 product revenue rose to $107.1 mln, driven by VYJUVEK sales

• Net income for Q4 increased to $51.4 mln

• Company maintains strong cash position with $955.9 mln in cash and investments

Outlook

• Krystal Biotech expects VYJUVEK launch in Italy in 2H 2026

• Company plans to expand distributor network to over 40 countries by end of 2026

• Krystal Biotech projects FY 2026 non-GAAP R&D and SG&A expenses at $175 mln-$195 mln

Result Drivers

• VYJUVEK SALES - Strong demand for VYJUVEK in the U.S. and international markets drove Q4 revenue to $107.1 mln

• EUROPEAN PRICING DISCUSSIONS - Ongoing pricing negotiations in Germany and France expected to continue into 2026 and 2027, respectively

• CYSTIC FIBROSIS PROGRAM - Positive clinical update from Phase 1 study of KB407 for cystic fibrosis, confirming lung delivery and expression of CFTR protein

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Krystal Biotech Inc is $308.00, about 11.4% above its February 13 closing price of $276.45

• The stock recently traded at 34 times the next 12-month earnings vs. a P/E of 28 three months ago

Press Release: ID:nGNX6YF4TW

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.